ZeroStack agrees to sell Phatebo to New Horizon Pharma for €2.15 million

ZSTK•2026-11-09

ZeroStack agreed to sell its 100% stake in Phatebo to New Horizon Pharma for €2.15 million. The deal is subject to foreign direct investment clearance in Germany and other closing conditions.

ZeroStack agrees to sell Phatebo to New Horizon Pharma for €2.15 million

1. Sale agreement

Related News

American Financial Group publishes Q3 2026 earnings call transcript

Plains All American forecasts 2026 adjusted EBITDA of $2.88 billion, plus or minus $50 million

Brazil's CSN says CFO Antonio Marco Campos resigned

Sources

ZeroStack agrees to sell Phatebo to New Horizon Pharma for €2.15 million

ArriVent Biopharma presents Phase 1 data for ARR-217 in advanced solid tumors

Energy Fuels appoints Jeffrey Olsen to board